<DOC>
	<DOC>NCT01448187</DOC>
	<brief_summary>The aim of the study is to describe the characteristics of patients treated with Iressa (particularly age, gender, phenotype, histology and stage of disease, line of treatment and previous treatments, smoking history, conditions of initiation of treatment (presence of an EGFR-activating mutation) and to evaluate the impact of treatment on the health of the population concerned in terms of morbidity and mortality (clinical benefit, safety,...) and quality of life</brief_summary>
	<brief_title>Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa</brief_title>
	<detailed_description>Descriptive pharmacoepidemiological study of patients treated with Iressa</detailed_description>
	<criteria>Patients treated with Iressa Patient included in a therapeutic trial comprising protocol use of Iressa Patient included in a therapeutic trial (HurietSerusclat Act) Patient refusing to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Lung cancer, France</keyword>
</DOC>